Moteur de recherche d’entreprises européennes
UK funding (963 120 £) : Organisation du complexe inflammasome dans les maladies infectieuses et inflammatoires Ukri07/06/2023 UK Research and Innovation, Royaume Uni
Vue d’ensemble
Texte
Organisation du complexe inflammasome dans les maladies infectieuses et inflammatoires
| Abstract | Inflammation protects people against infections, but it can be over activated, for example in sepsis or sterile inflammation, where it causes severe disease. Sepsis caused 20% of all global deaths in 2017, but the severe disease caused by COVID-19 has markedly increased this death toll. Sterile inflammation underpins diseases such as arthritis, type II diabetes, cancer, chronic respiratory diseases, atherosclerosis, Alzheimer's and Parkinson's diseases with a growing global burden. In the UK over 20 million people live with arthritis and approximately 850,000 people live with dementia costing £26 billion a year with cases forecast to reach 2 million by 2051. Globally 545 million people live with chronic respiratory disease. Development of new drugs for sepsis and for chronic inflammatory conditions are badly needed because the current ones are either not very efficient and/or have nasty side effects. Receptors present inside the cell (NOD-like receptors (NLRs)) sense pathogens or sterile inflammatory stimuli to form a complex called the inflammasome which ultimately kills the cell. Inflammasome complexes are critical for driving inflammation so to develop better anti-inflammatory therapies it is essential to understand how the inflammasome complex is organized within cells which is the aim of this proposal. Here we will study how immune cells form the inflammasome within cells, how it may be disrupted and determine whether there are any consequences for the cell by this disruptive process. By determining the mechanisms by which inflammasomes form in response to bacterial infection and inflammatory stimuli this will help us identify new targets for anti-inflammatory drugs and hence help develop new therapies for many important diseases. |
| Category | Research Grant |
| Reference | MR/X000826/1 |
| Status | Active |
| Funded period start | 07/06/2023 |
| Funded period end | 06/06/2026 |
| Funded value | £963 120,00 |
| Source | https://gtr.ukri.org/projects?ref=MR%2FX000826%2F1 |
Participating Organisations
| University of Cambridge |
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : University of Cambridge, Cambridge, Royaume Uni.
